Catalysts / CRVO
Upcoming FDA decisions and readouts we track for CervoMed, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for CervoMed (CRVO, listed on Nasdaq). All of them concern Neflamapimod (Non-fluent variant primary progressive aphasia (biomarker data); Recovery after stroke; Non-fluent variant primary progressive aphasia).
First on the list: the Phase 2A readout for Neflamapimod (Non-fluent variant primary progressive aphasia (biomarker data)), guided by the company to Oct 2026. The furthest-out event tracked is Q1 2027. By stage, the upcoming rows are 3 Phase 2A readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| CervoMed CRVO · Nasdaq | Neflamapimod | Non-fluent variant primary progressive aphasia (biomarker data) | Oct 2026 company guidance |
Phase 2A readout | Verified | 8-K exhibit 99.1 ↗ | No |
| CervoMed CRVO · Nasdaq | Neflamapimod | Recovery after stroke | H2 2026 company guidance |
Phase 2A readout | Verified | 8-K exhibit 99.1 ↗ | No |
| CervoMed CRVO · Nasdaq | Neflamapimod | Non-fluent variant primary progressive aphasia | Q1 2027 company guidance |
Phase 2A readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList